Clinical Trial Update: Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating the efficacy and safety of a triple combination of chidamide, sintilimab, and bevacizumab as second-line therapy for advanced extr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Chidamide (chidamide)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Phase 2 | Status: RECRUITING